[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361155-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361155-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-comprehensive-review-of-radiomic-methodologies-for-assessing-tumor-response-to-immunotherapy-and-combination-therapies-review-article","A Comprehensive Review of Radiomic Methodologies for Assessing Tumor Response to Immunotherapy and Combination Therapies - Review Article","","Recent advances in genetic and molecular characterization of cancer have accelerated immunotherapy development by strengthening the host immune system’s ability to recognize and target malignant cells. However, not all patients respond, creating a need for dependable biomarkers that can predict responders and non-responders early. Conventional response assessment tools such as WHO criteria and RECIST were mainly designed for cytotoxic chemotherapy and may miss hyperprogressive disease. Imaging advances including CT, PET, MRI, and radiomics provide functional and metabolic insights that improve response prediction. This review synthesizes publicly available research and WHO reports, emphasizing high-mortality cancers and non-invasive methods for evaluating immunotherapy and combination therapies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-comprehensive-review-of-radiomic-methodologies-for-assessing-tumor-response-to-immunotherapy-and-combination-therapies-review-article/361155/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-comprehensive-review-of-radiomic-methodologies-for-assessing-tumor-response-to-immunotherapy-and-combination-therapies-review-article/361155.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are conventional response criteria like WHO and RECIST limited for immunotherapy assessment?","Question",{"text":63,"@type":64},"They were primarily developed for cytotoxic chemotherapy and may not capture atypical response patterns such as initial enlargement, later shrinkage, or new lesion emergence. They can also delay detection of hyperprogressive disease, affecting treatment decisions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How can CT, PET, MRI, and radiomics contribute to evaluating tumor response to immunotherapy?",{"text":68,"@type":64},"These imaging modalities provide functional and metabolic information that better reflects tumor biology. Radiomics extracts quantitative features from medical images to support non-invasive assessment of tumor microenvironment, heterogeneity, and progression.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the main goal of the review described in the document?",{"text":72,"@type":64},"To consolidate recent findings on non-invasive methodologies for predicting and assessing therapeutic efficacy of immunotherapy and combination therapies, with a focus on high-mortality cancer types, using publicly available research and WHO reports.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361155,1790977285,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[1875-6603/26](1875-6603/26 Send Orders for Reprints to reprints@benthamscience.net)[ Send Orders for Reprints to](1875-6603/26 Send Orders for Reprints to reprints@benthamscience.net)[ ](1875-6603/26 Send Orders for Reprints to reprints@benthamscience.net)[reprints@benthamscience.net](1875-6603/26 Send Orders for Reprints to reprints@benthamscience.net)  \n1  \nCurrent Medical Imaging  \nContent list available at: [https://benthamscience.com/journals/cmir](https://benthamscience.com/journals/cmir)  \nREVIEW ARTICLE  \nA Comprehensive Review of Radiomic Methodologies for Assessing Tumor Response to Immunotherapy and Combination Therapies  \nHaijun Tian1, Yawei Ma1, Li Zhu1, Yongle Yu1, Youfu Ma1, Xialing Huang2,* and Xu Liu1,*  \n1Guangxi Key Laboratory of Special Biomedicine; School of Medicine, Guangxi University, Nanning, 530004, Guangxi Zhuang Autonomous Region, China  \n2Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China  \nAbstract:  \nRecent advances in the genetic and molecular characterization of cancer have significantly enhanced the development of immunotherapies, which bolster the host immune system’s ability to recognize and target malignant cells, thereby promoting immune responses and inhibiting tumor progression and metastasis. Despite these promising developments, not all patients benefit from immunotherapy, underscoring the urgent need for reliable biomarkers to facilitate early, predictive identification of responders and non-responders. Conventional methods for evaluating treatment response, such as the World Health Organization (WHO) criteria and the Response Evaluation Criteria in Solid Tumors (RECIST), which were primarily designed for cytotoxic chemotherapy, exhibit notable limitations. These criteria may fail to detect hyperprogressive disease in a timely manner, thereby hindering optimal treatment decision-making. Recent technological advancements in imaging modalities, including CT, PET, MRI, and radiomics, have provided critical functional and metabolic insights that enhance the evaluation and prediction of responses to immunotherapy. This review consolidates the latest findings from publicly available research and WHO reports, with a particular focus on highmortality cancer types, and examines recent developments in non-invasive methodologies for predicting and assessing the therapeutic efficacy of immunotherapy and its combination therapies.  \nKeywords: Radiomics, Immunotherapy, CT, PET, MRI, RECIST.  \n\n| Article History | Received: May 10, 2025 | Revised: August 08, 2025 | Accepted: August 21, 2025 |\n| --- | --- | --- | --- |\n\n1. INTRODUCTION  \nImmunotherapy, an emerging therapeutic modality, holds considerable promise in enhancing both the survival and quality of life for cancer patients, unlike traditional therapies, which directly target and eliminate tumor cells. Immunotherapy functions by stimulating the immune system to autonomously recognize and attack cancerous cells, thereby eliciting sustained therapeutic effects and the formation of immune memory. Furthermore, immunotherapy can be combined effectively with other treatment modalities, such as chemotherapy and radiotherapy, thereby broadening the therapeutic options.  \nA major clinical challenge in the field is predicting which patients are likely to benefit from immunotherapy. Identifying  \n* Address correspondence to these authors at the Guangxi Key Laboratory of Special Biomedicine; School of Medicine, Guangxi University, Nanning, 530004, Guangxi Zhuang Autonomous Region, China and Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China;  \n[E-mails: wendaoliuxu@163.com](E-mails: wendaoliuxu@163.com), [hxlsummering@163.com](hxlsummering@163.com)  \nindividuals who exhibit treatment resistance is critical, as it conserves resources, minimizes unnecessary interventions, and ","cbCaimsr1381qoRK","https://ap.wps.com/l/cbCaimsr1381qoRK","pdf",14740590,21,"English","# Abstract\n# 1. INTRODUCTION\n## Immunotherapy and its clinical promise\n## Limitations of conventional criteria (WHO, RECIST)\n## Emerging response standards (irRC, irRECIST, iRECIST)\n## Role of imaging and radiomics\n# 2. METHODS","[{\"question\":\"Why are conventional response criteria like WHO and RECIST limited for immunotherapy assessment?\",\"answer\":\"They were primarily developed for cytotoxic chemotherapy and may not capture atypical response patterns such as initial enlargement, later shrinkage, or new lesion emergence. They can also delay detection of hyperprogressive disease, affecting treatment decisions.\"},{\"question\":\"How can CT, PET, MRI, and radiomics contribute to evaluating tumor response to immunotherapy?\",\"answer\":\"These imaging modalities provide functional and metabolic information that better reflects tumor biology. Radiomics extracts quantitative features from medical images to support non-invasive assessment of tumor microenvironment, heterogeneity, and progression.\"},{\"question\":\"What is the main goal of the review described in the document?\",\"answer\":\"To consolidate recent findings on non-invasive methodologies for predicting and assessing therapeutic efficacy of immunotherapy and combination therapies, with a focus on high-mortality cancer types, using publicly available research and WHO reports.\"}]","A Comprehensive Review of Radiomic Methodologies for Assessing Tumor Response to Immunotherapy and Combination Therapies - Review Article | PDF",1790143336,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1a0b1c161eb8b2bd6cdfd393334fd8a.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbb66a74416fefe295b31f8dcf1b749a.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ea8b9bddebe31e9874ff710ac6606ba.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43964fda4c0b93098366be584fcbd38d.webp",980,1385]